Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir and Asunaprevir in Japanese HCV Genotype 1
NCT01051414Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daclatasvir and asunaprevir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability based on related serious adverse events (SAEs) and discontinuations due to related AEs at Week 4 and Sustained Virologic Response at 12 weeks post-treatment. Started Apr 2010; status: completed.
02
Drugs
daclatasvirasunaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01051414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051414.